Immunodeficiency

Primary immunodeficiencies (PIDs), also known as inborn errors of immunity (IEI) are a group of more than 400 potentially serious disorders that can lead to frequent or severe infections, swellings and autoimmune problems. PID/IEI discorders can be caused by defects in genes that control the immune system, and may be inherited.  

Information for Patients and Carers

Fast Facts abour PID/IEI 

Common Variable Immunodeficiency (CVID) Updated October 2021

Immunoglobulin Replacement Therapy (IRT) Updated October 2021

Primary Immunodeficiency (Inborn Errors of Immunity) Updated October 2021

Severe Combined Immunodeficiency (SCID) Updated October 2021

Subcutaneous Immunoglobulin (SCIg) Therapy - General Information Updated August 2021

Subcutaneous Immunoglobulin (SCIg) Therapy - Equipment Checklist

Subcutaneous Immunoglobulin (SCIg) Therapy - Infusion Checklist

Information for Health Professionals

ASCIA Position Statement - Immunoglobulin Replacement Therapy (IRT) in Primary Immunodeficiency (PID) New September 2021

ASCIA Immunodeficiency Strategy for Australia and New Zealand 

References - Immunodeficiency 

References - Hereditary Angioedema (HAE) 

ASCIA Webinar - HAE

ASCIA Position Paper and Management Plan - Hereditary Angioedema (HAE) 

References - Hereditary Angioedema (HAE)

ASCIA Clinical Update - Primary Immunodeficiencies (PID) 

ASCIA Position Statement - Subcutaneous Immunoglobulin (SCIg) 

ASCIA Guide – Setting up a Subcutaneous Immunoglobulin (SCIg) program in a hospital 

ASCIA Guidelines for Diagnosis and Management of Severe Combined Immunodeficiency (SCID) in Australia and New Zealand: A TAPID Consensus Guideline

ASCIA Guidelines - Standardised IVIg Infusion Rates for IRT

ASCIA SCIg Treatment Plan 

ASCIA Transfer Care Plan for patients on IRT (immunoglobulin replacement therapy) 

ASCIA Travel Plan for patients on SCIg (subcutaneous immunoglobulin) therapy 

ASCIA ID Register How to access information (available to Members Only)

Content updated November 2021